Total Valuation
Alzamend Neuro has a market cap or net worth of $363.60 million. The enterprise value is $364.72 million.
| Market Cap |
363.60M |
| Enterprise Value |
364.72M |
Important Dates
| Earnings Date |
n/a |
| Ex-Dividend Date |
n/a |
Share Statistics
Alzamend Neuro has 82.26 million shares outstanding.
| Shares Outstanding |
82.26M |
| Share Change (YoY) |
n/a |
| Share Change (QoQ) |
+15.45% |
| Owned by Insiders (%) |
40.23% |
| Owned by Institutions (%) |
6.12% |
| Float |
37.11M |
Valuation Ratios
| PE Ratio |
n/a |
| Forward PE |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
n/a |
| P/FCF Ratio |
n/a |
| PEG Ratio |
n/a |
Enterprise Valuation
| EV / Earnings |
n/a |
| EV / Sales |
n/a |
| EV / EBITDA |
n/a |
| EV / EBIT |
n/a |
| EV / FCF |
n/a |
Financial Position
| Current Ratio |
0.38 |
| Quick Ratio |
-7.07 |
| Debt / Equity |
n/a |
| Debt / EBITDA |
n/a |
| Debt / FCF |
n/a |
Financial Efficiency
| Return on Equity (ROE) |
-1,103.83% |
| Return on Assets (ROA) |
n/a |
| Return on Capital (ROIC) |
n/a |
| Revenue Per Employee |
n/a |
| Profits Per Employee |
n/a |
| Employee Count |
1 |
| Asset Turnover |
n/a |
| Inventory Turnover |
n/a |
Taxes
| Income Tax |
n/a |
| Effective Tax Rate |
n/a |
| Taxes as % of Revenue |
n/a |
Stock Price Statistics
| Beta (1Y) |
n/a |
| Total Price Change | -57.56% |
| 50-Day Moving Average |
7.68 |
| 200-Day Moving Average |
7.68 |
| Average Volume (30 Days) |
4,284,127 |
Short Selling Information
The latest short interest is 153,510, so 0.19% of the outstanding shares have been sold short.
| Short Interest |
153,510 |
| Short % of Shares Out |
0.19% |
| Short Ratio (days to cover) |
0.05 |
Income Statement
| Revenue |
n/a |
| Gross Profit |
n/a |
| Operating Income |
n/a |
| Net Income |
-5.05M |
| Net Income Common |
n/a |
| EBITDA |
n/a |
| EBIT |
n/a |
| Earnings Per Share (EPS) |
-$0.06 |
Full Income Statement
Balance Sheet
The company has $40,737 in cash and $1.16 million in debt, giving a net cash position of -$1.12 million or -$0.01 per share.
| Cash & Cash Equivalents |
40,737 |
| Total Debt |
1.16M |
| Net Cash |
-1.12M |
| Net Cash Per Share |
-$0.01 |
| Book Value |
-1.30M |
| Book Value Per Share |
-0.02 |
| Working Capital |
-1.30M |
Full Balance Sheet
Cash Flow
| Operating Cash Flow |
n/a |
| Capital Expenditures |
n/a |
| Free Cash Flow |
n/a |
| FCF Per Share |
n/a |
Cash Flow Statement
Margins
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| EBITDA Margin |
n/a |
| EBIT Margin |
n/a |
| FCF Margin |
n/a |
Dividends & Yields
Alzamend Neuro does not appear to pay any dividends at this time.
| Dividend Per Share |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
-1.39% |
| FCF Yield |
n/a |
| Dividend Growth (YoY) |
n/a |
| Payout Ratio |
n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date |
n/a |
| Split Type |
n/a |
| Split Ratio |
n/a |